Navigation Links
Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Date:11/20/2013

to be an important product in the well-established $260 million pain market in the U.S. alone.  We look forward to continuing our dialogue with the Center for Veterinary Medicine regarding the AT-001 program."

Aratana will discuss these results in more detail when the final study reports are available.

About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner.  Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding development programs, trials, studies, and approval; the timing of the pivotal field effectiveness study for AT-001; the timing for approval and commercialization of AT-001; the safety of AT-001; the potential for AT-001 to be an important product in the pain market; and the Company's plans and opportunities.

These forward-looking statements are based on management's current expectations. These statements are neither prom
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
2. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
3. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
4. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
7. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
8. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
9. Aratana Therapeutics Completes $15 Million Series B Financing
10. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
11. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 20 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading,pharmaceutical ... that,the company was named as a Top 100 ... by China Council for International,Investment Promotion (CCIIP) and ... This ranking covers outsourcing services in IT,pharmaceutical, ...
... ... 7 of the Top 10 pharmaceutical and 3 of the Top 5 medical device companies. ... Charlottesville, VA, San Diego, ... provider of technology and information solutions for the life sciences industry announced today a continuing ...
... , , , SAN ... VIAP ), a biotechnology company focused on the development of ... announced that it received a Staff Determination letter, dated July ... Company has not regained compliance with the minimum $2,500,000 stockholders, ...
Cached Biology Technology:OpenQ Posts a 200% Revenue Growth in the First Half of 2009 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4
(Date:4/17/2014)... Ill. A drug under clinical trials to treat ... broad-spectrum drugs that act against various bacteria, fungal infections ... by University of Illinois chemists and collaborators. , Led ... team determined the different ways the drug SQ109 attacks ... to target other pathogens from yeast to malaria ...
(Date:4/17/2014)... new modeling study suggests that fish consumption advisories ... exposure to long-lived contaminants like persistent organic pollutants ... team of researchers including University of Toronto Scarborough ... looks at how different levels of environmental contamination, ... of chemicals in the body influenced exposure in ...
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2
... Institute of Singapore (GIS) and the Anhui Medical University, China, ... development of psoriasis, a common chronic skin disease. The ... Prof. Liu Jianjun, will be published online on 25 Jan. ... genetic variants in the human genomes of a large cohort ...
... effort to improve rice varieties, a Purdue University researcher was ... domesticated rice by using a process that focuses on one ... studying the gene that decides how many shoots will form ... the gene evolved over time through natural selection and human ...
... January 23, 2009New technology deployed on airplanes is ... Island tropical forests from non-native plants and other ... Service and Carnegie Institution scientists involved in the ... journal Ecosystems and hope it will ...
Cached Biology News:Compromised skin barrier function plays a role in psorasis development 2Gene's past could improve the future of rice 2Scientists use lasers to measure changes to tropical forests 2
... is one of several isoprostanes produced from arachidonic ... renal vasoconstrictor in the rat. 8-iso PGE2 inhibits ... of 0.5 and 5 µM, respectively. When infused ... a concentration of 4 mg/kg/min, 8-iso PGE2 decreases ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: